Street View: J&J poised for growth despite US drug-pricing deal, talc claims

Johnson & Johnson JNJ.N on Wednesday forecast 2026 sales and profit above Wall Street estimates, even with the expected impact of a drug pricing deal with the Trump administration and about $500 million in expected tariffs it will have to absorb in its medical devices business
On Tuesday, a court-appointed special master recommended that expert testimony linking the company's talc products to ovarian cancer be allowed in court

On average, 28 analysts rate the stock "buy"; their median PT is $217, according to data compiled by LSEG

SOLID START TO 2026

RBC Capital Markets ("outperform"; PT: $240) says JNJ's Q4'25 results and 2026 outlook dispel concerns around healthcare utilization that drove a pullback in medtech stocks in recent weeks

J.P.Morgan ("neutral"; PT: $225) says "looking longer-term, we see JNJ entering a window of sustained, healthy growth as Stelara (psoriasis drug) headwinds ease and the company commercializes its broad late-stage pipeline"

TD Cowen ("buy"; PT: $250) says JNJ's pharma and devices franchises should sustain the momentum secured in 2H'25 throughout 2026 and into the outyears

Wolfe Research ("outperform"; PT: $260) says "talc happens, but JNJ's fundamental story remains clean"